October 16, 2012
$30.9M Series B Investment closed and Joel Martin appointed as President and CEO
September 07, 2011
Cebix to Chair Symposium on C-Peptide and the Pathophysiology of Diabetes at European Association for the Study of Diabetes Annual Meeting 2011
C-peptide is a 31 amino acid residue peptide derived from proinsulin (see schematic below), which is synthesized in the pancreatic beta cells. In healthy individuals, C-peptide and insulin are co-secreted in equal amounts into the circulation. In patients with type 1 and some patients with type 2 diabetes, destruction of the beta cells results in deficiency of both insulin and C-peptide. These patients receive insulin injections to compensate for the lack of endogenous insulin production, but no replacement of C-peptide is given.
Schematic representation of human proinsulin. C-peptide is indicated in yellow and insulin’s A- and B- chains in red.
Cebix scientists have identified C-peptide as a biologically active endogenous peptide hormone implicated in vascular homeostasis in several tissues. In patients with diabetes, C-peptide deficiency, together with elevated blood glucose levels, contributes to a reduction in microvascular circulation and subsequent damage to the nerves, the kidneys, and the retina. Replacement of C-peptide in type 1 diabetes patients and in animal models of diabetes has been shown to prevent or slow the progression of long-term complications like neuropathies, retinopathy, and nephropathy.